Advertisement

Evidence for detection of rat P2X4 receptor expressed on cells by generating monoclonal antibodies recognizing the native structure

  • Tatsuhiro Igawa
  • Shuhei Kishikawa
  • Yoshito Abe
  • Tomohiro Yamashita
  • Saki Nagai
  • Mitsunori Shiroishi
  • Chinatsu Shinozaki
  • Hiroyuki Tanaka
  • Hidetoshi Tozaki-Saitoh
  • Makoto Tsuda
  • Kazuhide InoueEmail author
  • Tadashi UedaEmail author
Article

Abstract

P2X purinergic receptors are ATP-driven ionic channels expressed as trimers and showing various functions. A subtype, the P2X4 receptor present on microglial cells is highly involved in neuropathic pain. In this study, in order to prepare antibodies recognizing the native structure of rat P2X4 (rP2X4) receptor, we immunized mice with rP2X4’s head domain (rHD, Gln111–Val167), which possesses an intact structure stabilized by S-S bond formation (Igawa and Abe et al. FEBS Lett. 2015), as an antigen. We generated five monoclonal antibodies with the ability to recognize the native structure of its head domain, stabilized by S-S bond formation. Site-directed mutagenesis revealed that Asn127 and Asp131 of the rHD, in which combination of these amino acid residues is only conserved in P2X4 receptor among P2X family, were closely involved in the interaction between rHD and these antibodies. We also demonstrated the antibodies obtained here could detect rP2X4 receptor expressed in 1321N1 human astrocytoma cells.

Keywords

P2X4 receptor Neuropathic pain Monoclonal antibody FSEC 

Abbreviations

CD

Circular dichroism

CFA

Complete Freund’s adjuvant

ECD

Extracellular domain of P2X4 receptor

IFA

Incomplete Freund’s adjuvant

KLH

Keyhole limpet hemocyanin

PBS

Phosphate-buffered saline

rHD

Rat head domain of P2X4 receptor

TAPS

Trimethylammonium propyl sulfonate

Notes

Acknowledgements

We thank Dr. Jose Caaveiro of Kyshu University for critical readership of the manuscript. ITC measurements were supported by the Platform for Drug Discovery, Informatics, and Structural Life Science from the Ministry of Education, Culture, Sports, Science and Technology, Japan.

Funding information

This work was supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan to UT (23390155) and YA (18K06597) and by a grant from the Japan Foundation for Applied Enzymology.

Compliance with ethical standards

Conflicts of interest

Tatsuhiro Igawa declares that he has no conflict of interest.

Shuhei Kishikawa declares that he has no conflict of interest.

Yoshito Abe declares that he has no conflict of interest.

Tomohiro Yamashita declares that he has no conflict of interest.

Saki Nagai declares that she has no conflict of interest.

Mitsunori Shiroishi declares that he has no conflict of interest.

Chinatsu Shinozaki declares that he has no conflict of interest.

Hiroyuki Tanaka declares that he has no conflict of interest.

Hidetoshi Tozaki-Saitoh declares that he has no conflict of interest.

Makoto Tsuda declares that he has no conflict of interest.

Kazuhide Inoue declares that he has no conflict of interest.

Tadashi Ueda declares that he has no conflict of interest.

Ethical approval

All animal experiments were conducted according to the relevant national and international guidelines in the Act on Welfare and Management of Animals (Ministry of Environment of Japan) and the Regulation of Laboratory Animals (Kyushu University), and under the protocols approved by the Institutional Animal Care and Use Committee review panels at Kyushu University.

Supplementary material

11302_2019_9646_MOESM1_ESM.docx (107 kb)
ESM 1 (DOCX 107 kb)

References

  1. 1.
    Watkins LR, Maier SF (2003) Glia: a novel drug discovery target for clinical pain. Nat Rev Drug Discov 2(12):973–985CrossRefGoogle Scholar
  2. 2.
    Watkins LR, Milligan ED, Maier SF (2001) Spinal cord glia: new players in pain. Pain 93(3):201–205CrossRefGoogle Scholar
  3. 3.
    Watkins LR, Milligan ED, Maier SF (2001) Glial activation: a driving force for pathological pain. Trends Neurosci 24(8):450–455CrossRefGoogle Scholar
  4. 4.
    Tsuda M, Shigemoto-Mogami Y, Koizumi S, Mizokoshi A, Kohsaka S, Salter MW, Inoue K (2003) P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury. Nature 424(6950):778–783CrossRefGoogle Scholar
  5. 5.
    Coull JA, Beggs S, Boudreau D, Boivin D, Tsuda M, Inoue K, Gravel C, Salter MW, De Koninck Y (2005) BDNF from microglia causes the shift in neuronal anion gradient underlying neuropathic pain. Nature 438(7070):1017–1021CrossRefGoogle Scholar
  6. 6.
    Matsumura Y, Yamashita T, Sasaki A, Nakata E, Kohno K, Masuda T, Tozaki-Saitoh H, Imai T, Kuraishi Y, Tsuda M, Inoue K (2016) A novel P2X4 receptor-selective antagonist produces anti-allodynic effect in a mouse model of herpetic pain. Sci Rep 6:32461CrossRefGoogle Scholar
  7. 7.
    Nagata K, Imai T, Yamashita T, Tsuda M, Tozaki-Saitoh H, Inoue K (2009) Antidepressants inhibit P2X4 receptor function: a possible involvement in neuropathic pain relief. Mol Pain 5:20CrossRefGoogle Scholar
  8. 8.
    Kawate T, Michel JC, Birdsong WT, Gouaux E (2009) Crystal structure of the ATP-gated P2X(4) ion channel in the closed state. Nature 460(7255):592–598CrossRefGoogle Scholar
  9. 9.
    Hattori M, Gouaux E (2012) Molecular mechanism of ATP binding and ion channel activation in P2X receptors. Nature 485(7397):207–212CrossRefGoogle Scholar
  10. 10.
    Igawa T, Higashi S, Abe Y, Ohkuri T, Tanaka H, Morimoto S, Yamashita T, Tsuda M, Inoue K, Ueda T (2013) Preparation and characterization of a monoclonal antibody against the refolded and functional extracellular domain of rat P2X4 receptor. J Biochem 153(3):275–282CrossRefGoogle Scholar
  11. 11.
    Igawa T, Abe Y, Tsuda M, Inoue K, Ueda T (2015) Solution structure of the rat P2X4 receptor head domain involved in inhibitory metal binding. FEBS Lett 589(6):680–686CrossRefGoogle Scholar
  12. 12.
    Galfre G, Milstein C (1981) Preparation of monoclonal antibodies: strategies and procedures. Methods Enzymol 73:3–46CrossRefGoogle Scholar
  13. 13.
    Goding JW (1980) Antibody production by hybridomas. J Immunol Methods 39(4):285–308CrossRefGoogle Scholar
  14. 14.
    Toyomitsu E, Tsuda M, Yamashita T, Tozaki-Saitoh H, Tanaka Y, Inoue K (2012) CCL2 promotes P2X4 receptor trafficking to the cell surface of microglia. Purinergic Signal 8(2):301–310CrossRefGoogle Scholar
  15. 15.
    Shiroishi M, Moriya M, Ueda T (2016) Micro-scale and rapid expression screening of highly expressed and/or stable membrane protein variants in Saccharomyces cerevisiae. Protein Sci 25(10):1863–1872CrossRefGoogle Scholar
  16. 16.
    Shoyama Y, Fukada T, Murakami H (1995) Production of monoclonal antibodies and ELISA for the baine and codeine. Cytotechnology 19(1):55–61CrossRefGoogle Scholar
  17. 17.
    Kawate T, Gouaux E (2006) Fluorescence-detection size-exclusion chromatography for precrystallization screening of integral membrane proteins. Structure 14(4):673–681CrossRefGoogle Scholar
  18. 18.
    Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83(2):435–445Google Scholar
  19. 19.
    Mihara M, Kasutani K, Okazaki M, Nakamura A, Kawai S, Sugimoto M, Matsumoto Y, Ohsugi Y (2005) Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol 5(12):1731–1740CrossRefGoogle Scholar

Copyright information

© Springer Nature B.V. 2019

Authors and Affiliations

  • Tatsuhiro Igawa
    • 1
  • Shuhei Kishikawa
    • 1
  • Yoshito Abe
    • 1
  • Tomohiro Yamashita
    • 2
  • Saki Nagai
    • 1
  • Mitsunori Shiroishi
    • 1
  • Chinatsu Shinozaki
    • 1
  • Hiroyuki Tanaka
    • 3
  • Hidetoshi Tozaki-Saitoh
    • 4
  • Makoto Tsuda
    • 4
  • Kazuhide Inoue
    • 5
    Email author
  • Tadashi Ueda
    • 1
    Email author
  1. 1.Department of Protein Structure, Function and Design, Graduate School of Pharmaceutical SciencesKyushu UniversityFukuokaJapan
  2. 2.Department of Global Health-Care, Graduate School of Pharmaceutical SciencesKyushu UniversityFukuokaJapan
  3. 3.Department of Pharmacognosy Graduate School of Pharmaceutical SciencesKyushu UniversityFukuokaJapan
  4. 4.Department of Life Innovation, Graduate School of Pharmaceutical SciencesKyushu UniversityFukuokaJapan
  5. 5.Department of Molecular and System Pharmacology, Graduate School of Pharmaceutical SciencesKyushu UniversityFukuokaJapan

Personalised recommendations